Literature DB >> 35519824

Letter to editor: Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum.

Andrés A Maldonado1, Robert J Spinner1, Jodi M Carter2, Christopher J Klein3.   

Abstract

The data summarized in this letter provide further evidence that the pathogenic mechanism underlying peripheral nerve enlargement as a phenotypic manifestation in PROS (PIK3CA-related overgrowth spectrum) may be genetically distinct from that of intraneural perineuriomas or soft tissue perineuriomas.
© 2022 The Author(s).

Entities:  

Year:  2022        PMID: 35519824      PMCID: PMC9065421          DOI: 10.1016/j.xhgg.2022.100110

Source DB:  PubMed          Journal:  HGG Adv        ISSN: 2666-2477


We read with interest the recent article by Koutlas et al., “Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum.” All three cases exhibit the phenotypic characteristics of hemifacial overgrowth, polypoid lesions on the tongue/buccal commissure, and segmental arrested development of the roots of teeth. All three cases showed similar histopathological features including “perineuriomatous pseudo-onion bulbs” and had PIK3CA mutations identical to those previously described in PIK3CA-related overgrowth syndrome (PROS). Given the nerve enlargement and perineuriomatous pseudo-onion bulbs in these cases—features that show some histologic overlap with perineurial tumors—at the encouragement of the primary author of the original article, we examined exome sequencing data from our previously published series of 16 patients with intraneural perineuriomas (in which we identified frequent TRAF7 mutations) and 14 patients with soft tissue perineuriomas (in which we found frequent deletions in the NF2 and NF1 loci but no TRAF7 mutations)., Reexamination revealed no evidence of a pathogenic PIK3CA mutation in any of these cases. These data provide further evidence that the pathogenic mechanism underlying peripheral nerve enlargement as a phenotypic manifestation in PROS (as described by Koutlas et al.) is genetically distinct from that of intraneural perineuriomas or soft tissue perineuriomas. Accordingly, it would be of interest to determine whether TRAF7 mutations or large gene rearrangements are present in the three cases described by the authors. Continued efforts to examine somatic mutations broadly with perineurial pathological features will be important with PIK3CA, TRAF7, and deletions of NF2, NF1 currently established as associated.
  4 in total

1.  Genomic analysis reveals frequent TRAF7 mutations in intraneural perineuriomas.

Authors:  Christopher J Klein; Yanhong Wu; Mark E Jentoft; Georges Mer; Robert J Spinner; P James B Dyck; Peter J Dyck; Michelle L Mauermann
Journal:  Ann Neurol       Date:  2017-01-28       Impact factor: 10.422

2.  PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.

Authors:  Kim M Keppler-Noreuil; Jonathan J Rios; Victoria E R Parker; Robert K Semple; Marjorie J Lindhurst; Julie C Sapp; Ahmad Alomari; Marybeth Ezaki; William Dobyns; Leslie G Biesecker
Journal:  Am J Med Genet A       Date:  2014-12-31       Impact factor: 2.802

3.  Recurrent Genomic Alterations in Soft Tissue Perineuriomas.

Authors:  Jodi M Carter; Yanhong Wu; Melissa M Blessing; Andrew L Folpe; Erik C Thorland; Robert J Spinner; Mark E Jentoft; Chen Wang; Saurabh Baheti; Zhiyv Niu; Michelle L Mauermann; Christopher J Klein
Journal:  Am J Surg Pathol       Date:  2018-12       Impact factor: 6.394

4.  Orofacial overgrowth with peripheral nerve enlargement and perineuriomatous pseudo-onion bulb proliferations is part of the PIK3CA-related overgrowth spectrum.

Authors:  Ioannis G Koutlas; Ana-Lia Anbinder; Rana Alshagroud; Ana Sueli Rodrigues Cavalcante; Mohammed Al Kindi; Molly M Crenshaw; Julie C Sapp; Hannah Kondolf; Marjorie J Lindhurst; Jeffrey N Dudley; Jennifer J Johnston; Elyse Ryan; Keith Rafferty; Arupa Ganguly; Leslie G Biesecker
Journal:  HGG Adv       Date:  2020-08-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.